博瑞醫藥(688166.SH)大跌超18% 強蹭瑞德西韋熱點上交所予以監管關注
格隆匯3月2日丨博瑞醫藥(688166.SH)大跌18.25%報50.99元,暫成交3.5億元,最新總市值209億元。上交所週日下發公告,對博瑞醫藥予以監管關注,並對其時任董事會祕書王徵野予以通報批評。經查明,博瑞醫藥於2月12日披露《關於抗病毒藥物研製取得進展的公告》稱,公司成功開發了瑞德西韋原料藥合成工藝和製劑技術,並已經批量生產出瑞德西韋原料藥,瑞德西韋製劑批量化生產正在進行中。經核實,公司公告中所稱“批量生產”實際為藥品研發中小試、中試等批次的試驗性生產。公司尚未取得藥監部門批准,也未取得專利權人授權,不具備進行藥物商業化批量生產的應有資質。此前公司股價一度因“已開始生產瑞德西韋原料藥”而連日大漲。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.